Skip to Content

Gadobenate Dimeglumine Dosage

Medically reviewed on July 24, 2018.

Applies to the following strengths: 529 mg/mL

Usual Adult Dose for CNS Magnetic Resonance Imaging

0.1 mmol/kg (0.2 mL/kg) as a rapid bolus intravenous injection. To ensure complete injection of the medium, the injection should be followed by a saline flush of at least 5 mL.

Usual Adult Dose for Magnetic Resonance Angiography

MRA of renal and aorto-ilio-femoral vessels:

0.1 mmol/kg (0.2 mL/kg) as a rapid bolus intravenous injection followed by a saline flush of at least 20 mL either manually or using an automatic injector system.

Imaging may be started immediately after the administration of gadobenate meglumine, with scan delay calculated by test bolus or automatic bolus detection technique. If bolus timing is not determined by an automatic contrast detection pulse sequence, then a test bolus injection of 1-2 ml of gadobenate meglumine should be used to calculate the scan delay.

Usual Pediatric Dose for CNS Magnetic Resonance Imaging

2 years and older:
0.1 mmol/kg (0.2 mL/kg) as a rapid bolus intravenous injection. To ensure complete injection of the medium, the injection should be followed by a saline flush of at least 5 mL.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

US BOXED WARNING:
-NEPHROGENIC SYSTEMIC FIBROSIS (NSF): Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in such patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears to be highest among patients with chronic, severe kidney disease (GFR less than 30 mL/min/1.73m2) or acute kidney injury. Patients should be screened for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., greater than 60 years of age, hypertension, or diabetes), estimate the GFR through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration.

Safety and efficacy have not been established in patients younger than 2 years.

Consult WARNINGS section for additional precautions.

Dialysis

No adjustment recommended

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide